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Aim: Mad honey (grayanotoxin, GTX) poisoning is caused by a toxin binding to the sodium channels of a cell membrane. This study
investigates the dose-dependent effect of GTX on the cardiovascular system.
Materials and methods: Twenty-four male Sprague Dawley rats were divided into 4 equal groups. Group 1 was the control group and
was administered only saline. GTX-III was administered in doses of 200, 400, and 800 μg/kg for Groups 2, 3, and 4, respectively. After
GTX-III injection, blood pressure and heart rate were recorded using an electrophysiological data acquisition system.
Results: After 200 µg/kg GTX-III injection, at 31–60 min, the blood pressure decreased significantly from the 84 ± 8 mmHg value of the
control group to 53 ± 4 mmHg (P = 0.023). In the group to which 800 µg/kg GTX-III was administered, the blood pressure decreased
to 50 ± 7 mmHg and 54 ± 5 mmHg in the postinjection periods of 31–60 and 61–90 min, respectively. These values were significantly
different from the 70 ± 6 and 84 ± 8 mmHg values recorded for the control group. The heart rate in the group injected with 400 µg/kg
GTX-III decreased significantly 40 min after injection. In the 800 µg/kg GTX-III group, the heart rate decreased significantly 20 min
after injection.
Conclusion: According to our findings, the bradycardiac and hypotensive picture seen in patients applying to the clinic with mad honey
poisoning also emerges clearly in experimental animals at the high dose of 800 µg/kg GTX-III.
Key words: Mad honey, grayanotoxin, poisoning, cardiovascular system

1. Introduction
Mad honey poisoning is seen in settlement areas along
the Turkish Black Sea coast and generally involves
a clinical picture of bradycardia, hypotension, and
syncope (1,2). The toxic effect of mad honey stems from
the grayanotoxin (GTX) it contains. GTX is present
in rhododendron (forest rose) leaves and flowers.
Rhododendrons grow in the damp forests that extend
along the Black Sea coast (3). The toxins taken up
from Rhododendron species plants by the bees in this
region lead to poisoning from the honey made by these
bees (4). The GTX binds to sodium channels on cell
membranes. The binding unit is the group II receptor
site, localized on a site of the sodium channel involved
in the voltage-dependent activation and inactivation
(1,5). These compounds prevent inactivation. Thus,
excitable cells (nerve and muscle) are maintained in a
state of depolarization, during which entry of calcium
into the cells may be facilitated. This action is similar to
* Correspondence: drsuhaturkmen@hotmail.com
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that exerted by the alkaloids of Veratrum and aconites
(6). All the observed responses of skeletal and heart
muscles, nerves, and the central nervous system are
related to the membrane effects (7). It has been suggested
that sites of cardiac and respiratory activity of GTX are
within the central nervous system and that bradycardiac
effects of GTX are mediated by vagal stimulation at the
periphery (8,9). There have been no studies showing the
dose-dependent effect of GTX on the cardiovascular
system. Future experimental studies on this subject will
help physicians see the correlation between the clinical
picture and the amount of honey ingested by a patient
presenting to the emergency department with such
poisoning.
This study was intended to investigate the effect of
systemically administered GTX-III in varying doses on
the blood pressure, heart rate, and respiratory frequency
of rats under anesthesia.
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2. Materials and methods
2.1. Study design and setting
Approval of the local animal experiments ethics committee
was obtained for the procedures involved. All experiments
and the care and use of laboratory animals were carried
out in compliance with local guidelines and the European
Union Guide to the Care and Use of Experimental Animals.
2.2. Selection of participants
This experimental study used 24 adult male Sprague
Dawley rats weighing between 249 and 280 g (mean weight
260 g). Grayanotoxin III Hemi(ethyl acetate) adduct and
pure ethanol were purchased from Sigma, ketamine HCl
(Ketalar) from Pfizer, and xylazine HCl (Xylazine Bio
2%) from Intermed. GTX-III was first dissolved in pure
ethanol and a 2% solution obtained with the addition of
sterile saline (ethanol and saline, 2:98 volume). GTX-III
was administered intraperitoneally to 3 experimental
groups in dosages of 200 µg/kg, 400 µg/kg, or 800 µg/
kg. The control group was injected with 0.9% NaCl (1
mL/kg). General anesthesia was administered before the
experiment began with the intramuscular administration
of 90 mg/kg ketamine and 10 mg/kg xylazine.
2.3. Interventions
The 24 experimental animals were randomized into 4
groups: Group 1, the control group, was given 1 mL/kg
intraperitoneal 0.9% NaCl. Group 2 was given 200 µg/
kg GTX-III intraperitoneally. Group 3 was given 400 µg/
kg GTX-III intraperitoneally. Group 4 was given 800 µg/
kg GTX-III intraperitoneally. Experimental animals were
anesthetized with an injection of ketamine/xylazine and
additional doses were given to those requiring it. Rats were
placed face up on the surgical table for carotid cannulation.
Skin, fatty tissue, and submaxillary gland excision was
performed around the trachea in such a way as to expose
both carotid and jugular veins. The operating area flaps
were folded to the side and sutured. The trachea was
exposed by excising the lower part of the sternohyoid and
sternomastoid muscles in front of it. The left carotid was
suspended with 2 silk sutures (5/0). A pediatric catheter
(24 G) was carefully inserted inside the carotid and a knot
was made with silk suture from outside the vessel and
fixed.
2.4. Methods and measurements
Once cannulation was complete, animals were placed face
up and a pressure transducer (MLT0670 Disposable BP
(Blood Pressure) Transducer, AD Instruments, Castle Hill,
Australia) was inserted into the other end of the catheter to
measure blood pressure. The BP transducer was attached
to a BP amplifier (ML117 BP Amp, AD Instruments), and
that was attached to a 16-channel electrophysiological
data acquisition unit (PowerLab, AD Instruments). For
electrocardiogram (ECG) recording, gel was applied

to the animals’ front right and left and rear left legs and
crocodile clip-type ECG electrodes were attached. The
cables of these electrodes were attached to an amplifier
(ML136 Animal Bio Amp, AD Instruments) linked to the
PowerLab unit. Respiratory frequencies were recorded
with the help of a piezoelectric conducer attached to the
animals’ chests with an elastic FILE bandage (MLT1010
Piezo Electric Pulse Transducer, AD Instruments). Rats’
body temperatures were monitored with a rectal probe
throughout the experiment and maintained at 37 °C with a
homeothermic blanket system (Harvard Homoeothermic
Blanket, Harvard Instruments, South Natick, MA,
USA). Rats were attached to the electrophysiological
data acquisition unit and ECG, blood pressure, heart
rate, and respiratory frequency were recorded for 120
min. Baseline ECG, pressure, and respiratory records
were first taken for 20 min. Subsequently, rats were
administered intraperitoneal doses of 0.9% NaCl or GTXIII. Data from the animals were monitored constantly in a
computer environment using LabChart software (v7.3, AD
Instruments) over 2 h. Data were recorded onto hard disk
for analysis after the experiment. ECG, blood pressure,
and respiratory frequency were converted to numerical
data with LabChart.
2.5. Analysis
Statistical comparisons were performed using SPSS 16.0
(SPSS Inc., Chicago, IL, USA). Conformity with normal
distribution was tested using the Shapiro–Wilk test.
Following one-way analysis of variance (ANOVA) for
normally distributed blood pressure data, the Bonferroni
post hoc test was used to determine statistical difference
between groups. Since heart rate and respiratory frequency
data did not conform to normal distribution, we used a
nonparametric statistical technique. The Mann–Whitney
U test with Bonferroni correction was applied to these data
following Kruskal–Wallis analysis of variance. Intragroup
comparisons were performed with repeated-measures
ANOVA and the paired samples t-test for variables having
normal distribution. The Friedman test and Wilcoxon
test with Bonferroni correction were used for intragroup
comparisons of variables with nonparametric distribution.
Data are expressed as mean ± standard error of the mean.
Statistical significance was set at P < 0.05.
3. Results
The effect of systemic administration of GTX-III on
arterial blood pressure was monitored. On the basis of
the data obtained we compared preinjection pressure
levels and minimum blood pressure values at intervals of
0–30, 31–60, and 61–90 min after injection between the
groups. Mean arterial pressures before injection in Group
1, Group 2, Group 3, and Group 4 were 87 ± 4 mmHg, 76
± 4 mmHg, 79 ± 8 mmHg, and 80 ± 5 mmHg, respectively.
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No statistically significant difference was seen between the
groups in terms of blood pressure values recorded before
injection (P > 0.05).
Blood pressure after 0.9% NaCl injection in the control
group at intervals of 0–30, 31–60, and 61–90 min was 70 ±
6 mmHg, 84 ± 8 mmHg, and 83 ± 9 mmHg. No significant
difference was determined between the time-dependent
blood pressure values in the control group. In Group 2, a
statistically significant fall to 53 ± 4 mmHg was observed
at 31–60 min after injection compared to the control
group (P = 0.023). In Group 3, while a partial decrease
was determined in blood pressure values measured at the
various time intervals, there was no statistical difference
between this value and that of the control group. Blood
pressure in Group 4 fell to 50 ± 7 mmHg and 54 ± 5
mmHg at 31–60 and 61–90 min after injection. Compared
with blood pressure values for the same intervals in the
control group, the decrease in Group 4 was statistically
significant (P = 0.011 and P = 0.011). Statistical analysis
was performed using the Bonferroni post hoc test after
ANOVA.
Animals in the groups administered GTXIII underwent hypotensive attack throughout the
experimental period after GTX-III injection. An average
of 4 hypotensive attacks took place during the 90-min
experimental period. There was no difference between
the GTX-III groups in terms of number of hypotensive
attacks, and attack numbers did not increase in a GTX-III
dose-dependent manner (Figure 1).
Rats’ heart rates before injection (0.9% NaCl or GTXIII) were 291 ± 30/min, 258 ± 22/min, 301 ± 13/min, and
225 ± 8/min in Group 1, Group 2, Group 3, and Group 4,

4. Discussion
While studies on this subject state that the severity of
poisoning findings is correlated with the amount of honey
ingested, there have been no studies showing a correlation
between the level of toxin and the clinical picture (10).
This study shows the correlation between severity of
poisoning and amount of ingested toxin. Individual
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respectively. There was no statistically significant difference
between the groups in terms of preinjection baseline heart
rate values (P > 0.05).
In Group 3, heart rate decreased significantly 40 min
after injection compared to the control group, and this
significant fall persisted until the end of the experiment
(P < 0.01 for 40–90 min). In Group 4, heart rate decreased
significantly 20 min after injection compared to the
control group, and this significant fall also persisted until
the end of the experiment (P < 0.05 for 20–30 min; P <
0.01 for 40–90 min). Heart rate data were compared using
the Mann–Whitney U test after Kruskal–Wallis analysis of
variance (Figures 2 and 3).
A piezoelectric transducer was used to determine the
effect of doses of GTX-III injected intraperitoneally on
respiratory frequency, and frequency was monitored for
each animal. Mean preinjection respiratory frequency was
44 ± 3 breaths/min, and there was no statistically significant
difference between the groups (P > 0.05). Respiratory
frequency rose in a time-dependent manner, especially
in Group 4, but this was not significant compared to the
control group (P > 0.05). Since the standard deviations of
respiratory data were very high, frequency is expressed as
percentage changes from preinjection values (Figure 4).

Before injection
Control

30
200 µg/kg GTX-III

60
400 µg/kg GTX-III

90

Time (min)

800 µg/kg GTX-III

Figure 1. The effect of systemic administration of GTX-III on mean arterial pressure.
*: Significant difference versus control group with ANOVA (Bonferroni post hoc test), P
< 0.05; # and ##: significant difference versus preinjection time with repeated-measures
ANOVA (paired sample t-test), P < 0.05 and P < 0.01, respectively; $, $$, and $$$:
significant difference versus preinjection time with repeated-measures ANOVA (paired
sample t-test), P < 0.05, P < 0.01, and P < 0.001, respectively; && and &&& = significant
difference versus preinjection time with repeated-measures ANOVA (paired sample
t-test), P < 0.05 and P < 0.01, respectively.
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Figure 2. The effect of systemic administration of GTX-III on heart rate.
*: Significant difference versus control group with Mann–Whitney U test with Bonferroni
correction, P < 0.0167.
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Figure 3. Heart rate data of the 4 groups.
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Before injection
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200 µg/kg GTX-III
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400 µg/kg GTX-III

90 Time (min)
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Figure 4. The effect of systemic administration of GTX-III on respiratory frequency.
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differences can be seen in mad honey poisoning. Cases
of poisoning with ingestion of 5–30 g have been reported
(11). Some cases proceed with mild symptoms, such as
nausea, vomiting, dizziness, and low blood pressure,
but cases of complete block and asystole have also been
reported (10,12). GTX can affect the central nervous
system, skeletomuscular system, respiratory system, heart,
and peripheral nervous system (8,13). In an experimental
study, Onat et al. showed the effects of GTX on the
respiratory system, central nervous system, and peripheral
nervous system by inducing bradycardia and respiratory
depression in rats. The same study also showed the
bradycardiac effect of GTX with bilateral vagotomy. This
shows that the effect of bradycardia is on the nervus vagus
and its extensions. In another study, Onat et al. showed
that bradycardia and respiratory depression in GTX
poisoning improved with the administration of atropine,
a nonspecific antimuscarinic agent. They also showed that
bradycardia improved with the administration of AF-DX
116, a selective M2 muscarinic agent, but that this had
no effect on respiratory depression (14). Studies have
shown that GTX is a fat-soluble toxin and increases Na
ion permeability by binding to voltage-dependent sodium
channels in the cell membrane. Kim et al. showed that it
increased Ca oscillation in inhibitory and excitatory nerve
tips. In addition, it was suggested that GTX intoxications
exhibit autonomic effects with an increase in GABA and
glutamate oscillation from these tips (15). GTX and toxins
such as tetrodotoxin, veratridine, and aconitine have been
shown to exhibit effects with modification in specific canal
functions (16).
GTX also has unique actions on Na+ channels, such as 1)
causing a shift of Na+ channel activation to hyperpolarizing
transmembrane potentials, 2) eliminating Na+ channel
inactivation, and 3) binding to the Na+ channel in its
open state, as established from the observation that these
toxins require repetitive rather than single long-lasting,
depolarizing stimuli to modify Na+ channels in excitable
cells of vertebrates (17).
Many case series and reports have shown that
patients presenting with GTX poisoning are subjected to
cardiovascular system effects. As shown in some studies,
this effect manifests itself as fluctuation in vital findings.
The scale of this fluctuation may range as far as asystolic
attack (18). Bradycardiac-tachycardiac and hypotensive
attacks were clearly visible in the time-dependent tension
and heart rate traces in our study. Baseline preinjection
mean arterial blood pressure ranged from 76 to 87 mmHg
in Group 1, Group 2, Group 3, and Group 4. Minimum
blood pressure values between 31 and 60 min after GTX
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injection decreased significantly in Group 2 and Group 4
compared to the control group (P < 0.05). On the other
hand, the significant fall in minimum blood pressure value
in Group 4 persisted (P < 0.05). Hypotensive attacks in
Group 2 and Group 4 were significant compared to the
control group. Although hypotensive attacks in Group 3
were lower than in the control group, the difference was
not statistically significant. An average of 4 hypotensive
attacks were observed over the 90-min recording period
in all groups administered GTX-III. These data account
for the hypotensive attacks observed clinically in
grayanotoxin patients. Investigation of the effect on heart
rate of 200, 400, and 800 µg/kg GTX-III showed that 200
µg/kg GTX-III had no effect. However, 400 µg/kg GTXIII decreased heart rate in a statistically significant manner
40 min after intraperitoneal injection, and this persisted
until the end of the study (P < 0.01). The effect of 800 µg/
kg GTX-III was manifested earlier compared to that of
400 µg/kg. A significant effect of the 800 µg/kg GTX-III
dose commenced 20 min after injection and persisted
until the end of the experiment (P < 0.05 for 20 and 30
min; P < 0.01 for 40 and 90 min). These data account for
the bradycardiac attacks observed clinically in patients
with grayanotoxin poisoning. While no effect was seen at
a low dose, bradycardia became more evident as dosage
increased. This finding is in agreement with the more
severe cardiac findings in patients with a higher ingestion
of honey in clinical series. Some experimental studies
have reported that grayanotoxin also has a suppressive
effect on respiratory functions (8,14). Although, in our
study, respiratory frequency increased toward the end
of the experiment in comparison to baseline values in
animals administered high doses of GTX-III, this rise
was not statistically significant. No decrease in respiratory
frequency was observed in the study.
The bradycardiac and hypotensive picture seen in
patients applying to the clinic with mad honey (GTX)
poisoning also emerged clearly in experimental animals at
the high dose of 800 µg/kg GTX-III. Our findings showed
a statistically insignificant rise in respiratory frequency
in experimental animals given high-dose GTX. With this
preliminary study, the determination of an experimental
GTX dosage needed to induce mad honey poisoning
in experimental animals and a detailed revelation of the
changes in blood pressure and heart rate at this dosage will
pave the way for further studies intended to determine
the extent of cardiovascular effects in GTX poisoning and
alternative treatment options. The present study is the
first animal study in which authors have used the GTX
administration model.
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